Investigating the survival prognosis in multiple myeloma (MM) patients, we have shown that PRC2 core genes, EZH2, SUZ12 and EED, were significantly overexpressed in MM cells compared to normal plasma cells, making these cells sensitive to EPZ-6438, an inhibitor of EZH2 [51]. This evidence concerns the gene EED and plasma cell myeloma.